Clinical Trials Logo
  1. Home
  2. Immune System Diseases
  3. NCT06107348
  4. Details
NCT06107348 Clinical Trial

COVID-19 Post-Vaccination Observation

Immune System Diseases Clinical Trial

Official title:
COVID-19 Post-Vaccination Observation on Immune Exhaustion

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT06107348
Other study ID # SARS-Immune-00
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date July 1, 2021
Est. completion date December 24, 2023

Study information
Verified date October 2023
Source Pachankis, Yang I., M.D.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study started after the second COVID-19 vaccination of the participant with blood spots appearing on the skin with severe arthritis. The study continued to the third-dose full vaccination of the participant with the recombined COVID-19 vaccination and afterwards. The study completed until intervention.

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 1
Est. completion date December 24, 2023
Est. primary completion date January 4, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility All COVID-19 vaccinated are eligible for inclusion.

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
China Residential Address Chongqing Chongqing

Sponsors (1)
Lead Sponsor Collaborator
Yang I. Pachankis, PhD

Country where clinical trial is conducted

China, 

References & Publications (1)

Pachankis YI. Questions of COVID-19: Institutional Derogations of Global Health. Lambert Academic Publishing. 2023. ISBN: 978-6206153849.

Outcome
Type Measure Description Time frame Safety issue
Primary Chemiluminescent Immunoassay for Human Immunodeficiency Virus 7 months
Primary Carcinoembryonic Antigen 7 months
Primary Alpha Fetoprotein 7 months
Primary Carbohydrate Antigen 19-9 7 months
Primary Mucin-16 7 months
Primary Cancer Antigen 15-3 7 months
Primary Prostate-Specific Antigen 7 months
Primary Leukocytes 7 months
Primary Leukocyte Percentage 7 months
Primary Cholesterol 7 months
See also
  Status Clinical Trial Phase
Recruiting NCT03663933 - Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04339777 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity Phase 2
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT02527187 - Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa Phase 2
Completed NCT01441076 - Anakinra for Behcet s Disease Phase 1/Phase 2
Completed NCT01472263 - Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Phase 3
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Suspended NCT04642066 - Cold Water Immersion and Atherosclerosis, Inflammation, Fat Accumulation and Lipid Profile Parameters N/A
Completed NCT02294552 - Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT Phase 2
Completed NCT01727973 - Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy Phase 1/Phase 2
Completed NCT04103099 - Impact of HLNatural Immune Supplement on Colds N/A
Recruiting NCT03344094 - Mechanism of Action of Ocrelizumab in Multiple Sclerosis N/A
Active, not recruiting NCT05445284 - Group Education Trial to Improve Transition for Parents of Adolescents With T1D N/A
Recruiting NCT06104111 - Epigenetic Memory of Vitamin D Supplementation Phase 1
Not yet recruiting NCT05616117 - Next-generation Effects of Vitamin D Supplementation in Pregnancy
Completed NCT01510626 - Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center Phase 1
Completed NCT01490177 - Single Center Food Allergy Oral Immunotherapy Study Phase 1
Completed NCT03922087 - No-worry Baby Project